Skip to main content
. 2016 May 17;1(3):e000045. doi: 10.1136/esmoopen-2016-000045

Figure 2.

Figure 2

Number of patients with disease control in the groups of grade 2–3 bevacizumab-induced HTN and without bevacizumab-related HTN. HTN, hypertension.